Literature DB >> 3950629

Cerebroventricular and intravascular metabolism of [125I]angiotensins in rat.

J W Harding, M S Yoshida, R P Dilts, T M Woods, J W Wright.   

Abstract

This study compared the metabolism of [125I]angiotensin II (AII), [125I]angiotensin III (AIII), and [125I]Sar1,Ile8-AII (SI-AII) in the vascular and cerebroventricular compartments. Using HPLC methods to monitor degradation the following t1/2 values were established in the vascular compartment: AII, 12.7 +/- 1.4 s; AIII, 16.3 +/- 0.7 s; and SI-AII, 100.7 +/- 7.3 s. HPLC analysis also revealed that [125I]AII is converted in an obligatory manner to [125I]AIII during its degradation sequence. Cerebrospinal fluid contained no degradative capacity for [125I]AII but exhibited a significant capacity to degrade [125I]AIII. A technique that combined the intra-cerebroventricular injection of [125I]angiotensins followed by focused microwave fixation to stop all peptidase activity was used to determine the half-life of [125I]angiotensins in the ventricular space. Results indicated very rapid metabolism of angiotensins with the following t1/2 values: AII, 23.0 s; and AIII, 7.7 s. This extremely rapid, differential, and sequential metabolism of AII and AIII in two relevant body fluid compartments underscores the need for caution when interpreting data derived from intravascular and intracerebroventricular application of angiotensins. In addition the faster metabolism of AIII than AII in the ventricular space indicates that the actual potency of AIII at central angiotensin receptors is being underestimated.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3950629     DOI: 10.1111/j.1471-4159.1986.tb00652.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  9 in total

Review 1.  The significance of brain aminopeptidases in the regulation of the actions of angiotensin peptides in the brain.

Authors:  Robert C Speth; Vardan T Karamyan
Journal:  Heart Fail Rev       Date:  2008-01-09       Impact factor: 4.214

Review 2.  Role of angiotensin III in hypertension.

Authors:  Annabelle Reaux-Le Goazigo; Xavier Iturrioz; Celine Fassot; Cedric Claperon; Bernard P Roques; Catherine Llorens-Cortes
Journal:  Curr Hypertens Rep       Date:  2005-04       Impact factor: 5.369

Review 3.  Aminopeptidase A inhibitors as centrally acting antihypertensive agents.

Authors:  Laurence Bodineau; Alain Frugière; Yannick Marc; Cédric Claperon; Catherine Llorens-Cortes
Journal:  Heart Fail Rev       Date:  2008-01-03       Impact factor: 4.214

4.  Angiotensin receptors from rat liver, brain and pituitary gland. Expression of two subtypes in Xenopus oocytes.

Authors:  B Cantau; S Bartolami; P P Baskevitch; F Desarnaud; D Chicot; S Jard
Journal:  Biochem J       Date:  1991-08-01       Impact factor: 3.857

Review 5.  A current view of brain renin-angiotensin system: Is the (pro)renin receptor the missing link?

Authors:  Adolfo E Cuadra; Zhiying Shan; Colin Sumners; Mohan K Raizada
Journal:  Pharmacol Ther       Date:  2009-08-31       Impact factor: 12.310

6.  Focus on Brain Angiotensin III and Aminopeptidase A in the Control of Hypertension.

Authors:  John W Wright; Shigehiko Mizutani; Joseph W Harding
Journal:  Int J Hypertens       Date:  2012-06-26       Impact factor: 2.420

Review 7.  Aminopeptidase N in arterial hypertension.

Authors:  Robert S Danziger
Journal:  Heart Fail Rev       Date:  2007-11-16       Impact factor: 4.214

Review 8.  Enzymatic pathways of the brain renin-angiotensin system: unsolved problems and continuing challenges.

Authors:  Vardan T Karamyan; Robert C Speth
Journal:  Regul Pept       Date:  2007-03-30

Review 9.  New insights into the importance of aminopeptidase A in hypertension.

Authors:  Shigehiko Mizutani; Masakazu Ishii; Akira Hattori; Seiji Nomura; Yasushi Numaguchi; Masafumi Tsujimoto; Hiroshi Kobayshi; Toyoaki Murohara; John W Wright
Journal:  Heart Fail Rev       Date:  2007-11-08       Impact factor: 4.214

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.